{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T09:15:59Z","timestamp":1717146959270},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T00:00:00Z","timestamp":1285027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s00280-010-1465-z","type":"journal-article","created":{"date-parts":[[2010,9,20]],"date-time":"2010-09-20T06:50:28Z","timestamp":1284965428000},"page":"139-145","source":"Crossref","is-referenced-by-count":4,"title":["Multimodal therapy for liver cirrhosis patients with advanced hepatocellular carcinoma"],"prefix":"10.1007","volume":"68","author":[{"given":"Hidenari","family":"Nagai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kanayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritaka","family":"Wakui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Momiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasukiyo","family":"Sumino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,21]]},"reference":[{"key":"1465_CR1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.1440","volume":"94","author":"DM Parkin","year":"2001","unstructured":"Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153\u2013156","journal-title":"Int J Cancer"},{"key":"1465_CR2","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.gastro.2004.09.018","volume":"127","author":"MC Yu","year":"2004","unstructured":"Yu MC, Yuan J-M (2004) Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127:S72\u2013S78","journal-title":"Gastroenterology"},{"key":"1465_CR3","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1053\/j.gastro.2004.09.011","volume":"127","author":"FX Bosch","year":"2004","unstructured":"Bosch FX, Ribes J, Diaz M et al (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127:S5\u2013S16","journal-title":"Gastroenterology"},{"key":"1465_CR4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1148\/radiology.140.1.7244243","volume":"140","author":"VP Chuang","year":"1981","unstructured":"Chuang VP, Wallace S (1981) Hepatic arterial embolization in the treatment of hepatic neoplasms. Radiology 140:51\u201358","journal-title":"Radiology"},{"key":"1465_CR5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1148\/radiology.148.2.6306721","volume":"148","author":"R Yamada","year":"1983","unstructured":"Yamada R, Sato M, Kawabata M et al (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148:397\u2013401","journal-title":"Radiology"},{"key":"1465_CR6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0016-5085(88)90436-2","volume":"94","author":"DY Lin","year":"1988","unstructured":"Lin DY, Liaw YF, Lee TY et al (1988) Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Gastroenterology 94:453\u2013456","journal-title":"Gastroenterology"},{"key":"1465_CR7","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/1097-0142(19911115)68:10<2150::AID-CNCR2820681011>3.0.CO;2-F","volume":"68","author":"K Ikeda","year":"1991","unstructured":"Ikeda K, Kumada H, Saitoh S et al (1991) Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. Cancer 68:2150\u20132154","journal-title":"Cancer"},{"key":"1465_CR8","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Montana X et al (2002) Barcelona liver cancer group. Arterial embolization or chemoembolization versus systemic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359:1734\u20131739","journal-title":"Lancet"},{"key":"1465_CR9","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164\u20131171","journal-title":"Hepatology"},{"key":"1465_CR10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1053\/j.gastro.2006.05.021","volume":"131","author":"K Takayasu","year":"2006","unstructured":"Takayasu K, Arii S, Ikai I et al (2006) Liver cancer study group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8,510 patients. Gastroenterology 131:461\u2013469","journal-title":"Gastroenterology"},{"key":"1465_CR11","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E","volume":"56","author":"K Okuda","year":"1985","unstructured":"Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Onishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918\u2013928","journal-title":"Cancer"},{"key":"1465_CR12","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/1097-0142(19841001)54:7<1461::AID-CNCR2820540740>3.0.CO;2-7","volume":"54","author":"N Nagasue","year":"1984","unstructured":"Nagasue N, Yukaya H, Hamada T, Hirosue S, Kanashima R, Inokuchi K (1984) The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer 54:1461\u20131465","journal-title":"Cancer"},{"key":"1465_CR13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000227477","volume":"52","author":"H Toyoda","year":"1995","unstructured":"Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, Kirishima S, Suga T, Takahashi M (1995) The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 52:295\u2013299","journal-title":"Oncology"},{"key":"1465_CR14","first-page":"1719","volume":"23","author":"K Murata","year":"2003","unstructured":"Murata K, Shiraki K, Kawakita T, Yamamoto N, Okano H, Nakamura M, Takahisa Sakai, Deguchi M, Ohmori S, Nakano T (2003) Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res 23:1719\u20131722","journal-title":"Anticancer Res"},{"key":"1465_CR15","first-page":"587","volume":"6","author":"K Okuda","year":"1999","unstructured":"Okuda K, Tanaka M, Shibata J, Ando E, Ogata T, Kinoshita H, Eriguchi N, Aoyagi S, Takikawa K (1999) Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncology Report 6:587\u2013591","journal-title":"Oncology Report"},{"key":"1465_CR16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2174\/157489208786242296","volume":"3","author":"H Nagai","year":"2008","unstructured":"Nagai H, Sumino Y (2008) Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. Recent Pat Anticancer Drug Discov 3:220\u2013226","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"2","key":"1465_CR17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3748\/wjg.v13.i2.280","volume":"13","author":"H Nagai","year":"2007","unstructured":"Nagai H, Kanayama M, Higami K et al (2007) Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. World J Gastroenterol 13(2):280\u2013284","journal-title":"World J Gastroenterol"},{"key":"1465_CR18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00280-008-0851-2","volume":"64","author":"M Kanayama","year":"2009","unstructured":"Kanayama M, Nagai H, Sumino Y (2009) Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 64:109\u2013114","journal-title":"Cancer Chemother Pharmacol"},{"key":"1465_CR19","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L et al (2004) BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099\u20137109","journal-title":"Cancer Res"},{"key":"1465_CR20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2007.15.5242","volume":"27","author":"A Moreno-Aspitia","year":"2009","unstructured":"Moreno-Aspitia A, Morton RF, Hillman DW et al (2009) Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central cancer treatment group and Mayo Clinic Trial N0336. J Clin Oncol 27:11\u201315","journal-title":"J Clin Oncol"},{"key":"1465_CR21","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","volume":"24","author":"GK Abou-Alfa","year":"2006","unstructured":"Abou-Alfa GK, Schwartz L, Ricci S et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293\u20134300","journal-title":"J Clin Oncol"},{"key":"1465_CR22","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1007\/BF00686685","volume":"33","author":"T Iwamiya","year":"1994","unstructured":"Iwamiya T, Sawada S, Ohta Y (1994) Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 33:S134\u2013S138","journal-title":"Cancer Chemother Pharmacol"},{"key":"1465_CR23","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/1097-0142(19900215)65:4<913::AID-CNCR2820650416>3.0.CO;2-9","volume":"65","author":"K Wakasa","year":"1990","unstructured":"Wakasa K, Sakurai M, Kuroda C et al (1990) Effect of transcatheter arterial embolization on the boundary architecture of hepatocellular carcinoma. Cancer 65:913\u2013919","journal-title":"Cancer"},{"key":"1465_CR24","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Chen HL, Girgis KR et al (1996) Production of vascular endotherial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096\u20131103","journal-title":"Nat Med"},{"key":"1465_CR25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCounter J (2003) The biology of VEGF and its receptors. Nat Med 9:669\u2013676","journal-title":"Nat Med"},{"key":"1465_CR26","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1158\/1078-0432.CCR-04-0181","volume":"10","author":"F Korangy","year":"2004","unstructured":"Korangy F, Ormandy LA, Bleck JS et al (2004) Spontaneous tumor-specific humoral and cellular immune response to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10:4332\u20134341","journal-title":"Clin Cancer Res"},{"key":"1465_CR27","doi-asserted-by":"crossref","first-page":"F41","DOI":"10.1084\/jem.193.11.F41","volume":"193","author":"EM Shevach","year":"2001","unstructured":"Shevach EM (2001) Certified professionals: CD4+ CD25+ suppressor T cell. J Exp Med 193:F41\u2013F46","journal-title":"J Exp Med"},{"key":"1465_CR28","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/1521-4141(200104)31:4<1247::AID-IMMU1247>3.0.CO;2-M","volume":"31","author":"LA Stephens","year":"2001","unstructured":"Stephens LA, Mottet C, Mason D, Powrie F (2001) Human CD4\u00a0+\u00a0CD25\u00a0+\u00a0thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 31:1247\u20131254","journal-title":"Eur J Immunol"},{"key":"1465_CR29","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1084\/jem.193.11.1285","volume":"193","author":"H Jonuleit","year":"2001","unstructured":"Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH (2001) Identification and functional characterization of human CD4\u00a0+\u00a0CD25\u00a0+\u00a0T cells with regulatory properties isolated from peripheral blood. J Exp Med 193:1285\u20131294","journal-title":"J Exp Med"},{"key":"1465_CR30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.iy.07.040189.001045","volume":"7","author":"TR Mosmann","year":"1989","unstructured":"Mosmann TR, Coffman RL (1989) Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145\u2013173","journal-title":"Annu Rev Immunol"},{"key":"1465_CR31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1074-7613(00)80533-6","volume":"8","author":"A O\u2019Garra","year":"1998","unstructured":"O\u2019Garra A (1998) Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8:275\u2013283","journal-title":"Immunity"},{"key":"1465_CR32","volume-title":"Essential immunology","year":"1997","unstructured":"Roitt I (ed) (1997) Essential immunology, 9th edn. Blackwell Science, Malden","edition":"9"},{"key":"1465_CR33","volume-title":"Immunology","author":"J Kuby","year":"2000","unstructured":"Kuby J, Cameron J, Todd C, Mitchell J (2000) Immunology, 4th edn. Freeman and Company, New York","edition":"4"},{"key":"1465_CR34","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.4049\/jimmunol.160.12.5869","volume":"160","author":"M Kobayashi","year":"1998","unstructured":"Kobayashi M, Kobayashi H, Polland RB et al (1998) A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 160:5869\u20135873","journal-title":"J Immunol"},{"key":"1465_CR35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1084\/jem.183.1.87","volume":"183","author":"L Zitvogel","year":"1996","unstructured":"Zitvogel L, Mayordomo JI, Tjandrawan T et al (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87\u201397","journal-title":"J Exp Med"},{"key":"1465_CR36","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.4049\/jimmunol.158.7.3359","volume":"158","author":"K Tsung","year":"1997","unstructured":"Tsung K, Meko JB, Peplinski GR et al (1997) IL-12 induces T helper 1-directed antitumor response. J Immunol 158:3359\u20133365","journal-title":"J Immunol"},{"key":"1465_CR37","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1073\/pnas.94.20.10833","volume":"94","author":"GJ Weiner","year":"1997","unstructured":"Weiner GJ, Liu HM, Wooldridge JE et al (1997) Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 94:10833\u201310837","journal-title":"Proc Natl Acad Sci USA"},{"key":"1465_CR38","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.4049\/jimmunol.161.6.3033","volume":"161","author":"H-M Hu","year":"1998","unstructured":"Hu H-M, Urba WJ, Fox BA (1998) Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from Type 2 to a type 1 cytokine profile. J Immunol 161:3033","journal-title":"J Immunol"},{"key":"1465_CR39","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00280-008-0685-y","volume":"62","author":"H Nagai","year":"2008","unstructured":"Nagai H, Miyaki D, Matsui T, Kanayama M, Higami K, Momiyama K, Ikehara T, Watanabe M, Sumino Y, Miki K (2008) Th1\/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy. Cancer Chemother Pharmacol 62:959\u2013963","journal-title":"Cancer Chemother Pharmacol"},{"key":"1465_CR40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00280-008-0866-8","volume":"64","author":"K Momiyama","year":"2009","unstructured":"Momiyama K, Nagai H, Sumino Y (2009) Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy. Cancer Chemother Pharmacol 64:271\u2013277","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1465-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1465-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1465-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T11:36:53Z","timestamp":1685792213000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1465-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,21]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["1465"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1465-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,21]]}}}